Cantor Fitzgerald Reaffirms Neutral Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $152.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 19.49% from the company’s current price.

A number of other analysts have also recently issued reports on the company. BMO Capital Markets raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Robert W. Baird raised their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $235.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Citigroup cut their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Three analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.39.

Sarepta Therapeutics Stock Up 0.1 %

SRPT stock opened at $127.21 on Friday. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The business has a 50 day moving average price of $137.26 and a two-hundred day moving average price of $132.66. The company has a market cap of $12.02 billion, a price-to-earnings ratio of 1,156.45 and a beta of 0.81. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period last year, the firm posted ($0.27) earnings per share. The business’s revenue was up 38.9% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics will post 1.47 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The disclosure for this sale can be found here. Insiders sold 52,801 shares of company stock valued at $8,399,586 in the last three months. Corporate insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Principal Securities Inc. bought a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $26,000. Dimensional Fund Advisors LP increased its stake in shares of Sarepta Therapeutics by 10.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 224,201 shares of the biotechnology company’s stock valued at $21,621,000 after purchasing an additional 20,923 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Sarepta Therapeutics by 125.3% in the 4th quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock valued at $4,777,000 after purchasing an additional 27,549 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Sarepta Therapeutics by 65.2% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,108 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 1,227 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $80,697,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.